Organization (Industry)
UCB PHARMA
ClinicalTrials.gov lists UCB PHARMA as lead sponsor of 406 trials, counting the companies grouped under it. UCB PHARMA itself has 31 active development programs and 31 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The dashed outline is the pace from the 6 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo UCB (Union Chimique Belge), via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers UCB PHARMA and 2 companies grouped under it: 406 lead-sponsored trials (276 its own, 130 in the grouped companies) and 16 legal-entity registrations (14 its own, 2 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| UCB BIOPHARMA | 129 | 1 |
| UCB BELGIUM | 1 | 1 |
Disease areas (163)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Epilepsy | 122 |
| Arthritis, Rheumatoid | 42 |
| Parkinson Disease | 39 |
| Inflammatory Bowel Diseases | 31 |
| Crohn Disease | 30 |
Showing 5 of 163 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 2 |
| 2024 | 2 |
| 2021 | 2 |
| 2020 | 6 |
| 2019 | 1 |
| 2018 | 3 |
| 2016 | 3 |
| 2015 | 6 |
| 2014 | 6 |
Showing 10 of 26 years.
Recruitment duration, a model prediction: none of the 276 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (31)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Brivaracetam | Epilepsy | Phase 3 | 17 |
| Lacosamide | Diabetic Neuropathies | Phase 3 | 6 |
| Lacosamide | Diabetes Mellitus | Phase 3 | 6 |
| Seletracetam | Epilepsy | Phase 3 | 4 |
| BRV 25 mg | Myoclonus | Phase 3 | 1 |
Showing 5 of 31 active programs.
Approved assets (31)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| LEVETIRACETAM | 43 |
| Certolizumab Pegol | 39 |
| Lacosamide | 34 |
| ROTIGOTINE | 31 |
| LEVOCETIRIZINE | 20 |
Showing 5 of 31 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 3 hit target (n=3) | 2 of 4 on time (n=4) |
Journals published in (163)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Epilepsia | 41 |
| Annals of the rheumatic diseases | 23 |
| Epilepsy & behavior : E&B | 22 |
| Neurology | 15 |
| The British journal of dermatology | 13 |
Showing 5 of 163 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 672 | 92 | 2025-11-18 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 8 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 18 | 2026-04-09 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| UCB Pharma S.A. | Braine-l'Alleud, BE | EMA, FDA, Health Canada |
Organization relationships (70)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Parexel | Uses vendor | 8 |
| University of California System | Co sponsors trial with | 5 |
| Parexel | Co sponsors trial with | 3 |
| University of Oxford | Co sponsors trial with | 3 |
| The Cleveland Clinic | Co sponsors trial with | 3 |
Showing 5 of 70 relationships.
Latest dated events (1,223)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,223 events.
Biomarker capability evidence (322)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC6 | Trial collaborator | Named in trial inclusion criteria |
| ACHE | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Primary endpoint in a Phase 3 trial |
| ALB | Trial sponsor | Primary endpoint in a Phase 3 trial |
Showing 5 of 322 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.